Eduardo Ramacciotti

ORCID: 0000-0002-5735-1333 · 2 papers in corpus
preprint 2026
Gestrinone Subdermal Bioabsorbable Implant for the Treatment of Endometriosis-Associated Pelvic Pain: A Phase II, Safety Randomised Clinical Trial
·doi:10.2139/ssrn.6509072
other 2025
Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain
Annals of medicine ·doi:10.1080/07853890.2025.2527352

BACKGROUND: Pelvic pain secondary to endometriosis is a disabling condition. There are multiple treatments available, with variable endpoints. No prospective controlled studies were carried out evaluating subdermal pellets of gestrinone in …